HPB wrapped 2025 Question Title * 1. Pick your top 10 best studies for HPB surgical oncology in 2024, in the following list (click on the links to access the publications): The Impact of KRAS Status on Long-Term Outcomes After Thermal Ablation and Hepatic Resection for Liver-Only Colorectal Metastases: A New Clue for Tailoring Surgical Strategy on Tumor Biology? PREHEP trial - Prehabilitation With Exercise and Nutrition to Reduce Morbidity of Major Hepatectomy in Patients With Sarcopenia AIO/CALGP/ACO-GAIN-Trial - Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer TESLA 1 - Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. PACYFIC trial - Small and Stable Pancreatic Cysts Are Reassuring During Surveillance: PREOPANC 2 - Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer COLLISION - Thermal ablation versus surgical resection of small-size colorectal liver metastases ENDURO - Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction AROD - Assessment of Residual or Resected Disappearing Liver Metastases After Chemotherapy ROCNROLL - Robotic versus laparoscopic hepatectomy for liver malignancies Personalized Surveillance Intervals for Intraductal Papillary Mucinous Neoplasm (IPMN): Multicenter Study Using Parametric Models PANDRA-II - Reconsidering Abdominal Drainage After Left Pancreatectomy Defining Biological Borderline Resectable Non-functioning Pancreatic Neuroendocrine Tumors JSAP05 - Neoadjuvant Chemotherapy with Gemcitabine and S-1 versus Upfront Surgery for Resectable Pancreatic Cancer Impact of pre-compression versus non-compression before parenchyma transection in left-sided pancreatic resection on the rate of clinically relevant pancreatic fistula: multicentre randomized clinical trial PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma PRICE2 - Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer Done